Irinotecan Glenmark

Irinotecan, the active ingredient in Irinotecan Glenmark, is a topoisomerase I inhibitor presented as an intravenous formulation for infusion use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients, interfering with DNA replication in rapidly dividing tumor cells and leading to cell death.

GNH USA supplies Irinotecan Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is indicated for colorectal cancer treatment, targeting tumor growth and progression.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. Advanced colorectal cancer: provides disease control in patients with unresectable disease. Colorectal cancer (first‑line therapy): used with fluoropyrimidines to enhance response rates.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly observed during infusion. - Diarrhea: may be mild to moderate and often requires supportive care. - Neutropenia: reduction in white blood cells increasing infection risk. - Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia: can lead to life‑threatening infections. - Acute severe diarrhea (colitis): may require hospitalization and intensive management. - Allergic reactions: including rash, pruritus, or anaphylaxis. - Hepatic or pulmonary toxicity: rare organ‑specific adverse events.

Before initiating Irinotecan therapy, clinicians should consider several safety measures to minimize risk.

Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia. Liver function assessment: evaluate hepatic enzymes as Irinotecan is metabolized hepatically. Bowel obstruction evaluation: assess for pre‑existing gastrointestinal blockage. Renal impairment dose adjustment: modify dosing in patients with reduced kidney function. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irinotecan can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Strong UGT1A1 inhibitors (e.g., atazanavir): may increase toxic metabolite levels, leading to severe neutropenia. - Potent CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations and risk of toxicity. - Live bacterial vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure. - Enzyme inducers (e.g., rifampicin): can lower drug levels, reducing efficacy. - Other myelosuppressive agents (e.g., carboplatin): may enhance bone‑marrow suppression.